
    
      We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent
      chemoradiotherapy as the adjunctive therapy before esophagectomy or as a definitive CRT would
      improve the therapeutic efficacy of TP-CCRT in patients with loco-regional esophageal
      squamous cell carcinoma.
    
  